Patient Portal Aegislabs: https//patientportal.aegislabs.com

Aegis TAT is the amount of time it takes from the moment a sample enters our lab tracking system till the moment test results are made public. The time it takes to get there is not included in this price. After collection, Aegis collaborates with all its collection partners to create the most of overnight shipment to its lab. Aegis. If there are any delays in the shipment process or weekend shipping schedules, this could delay the final Aegis report.

For The Most Up-to-date Information, Please Visit Patientportal.aegislabs.com.

The gateway will show that the sample has been received and testing has begun once it has been received by the lab and the testing has begun. The results will be posted on the door as soon as the testing is finished. When your test results are revealed, you will receive an email with the results. As a result of SARS-CoV-2 transmission, millions of people worldwide have been afflicted with various ailments.

You may also read:-

Health care practitioners, epidemiologists, virologists, and laboratory scientists have frequently found themselves fighting an uphill struggle in the dissemination and treatment of patients infected with COVID-19, despite substantial advances in their understanding of the virus causes COVID-19. Recently, we’ve learned that the SARS-CoV-2 virus, like many respiratory infections before it, has undergone mutation, which could contribute to enhanced infectivity and disease. The apparent rise in transmissibility of viral genetic variations such as B.1.1.7 and 501Y.V2 has piqued the interest of the general public and those helping treat COVID-19.

The ability of routinely used testing procedures to detect these novel genetic variations has also been questioned. Thermo Fisher Scientific TaqPathTM COVID-19 Combo Kit is used by Aegis Sciences Corporation for COVID-19 diagnostic testing. Three genomic targets are particular to SARS-CoV-2 that are being examined by this susceptible and focused technique. Current COVID variations are not likely to affect the sensitivity of the TaqPathTM COVID-19 Combo Kit, according to the FDA (i.e., B.1.17).

Patient Portal Aegislabs
Patient Portal Aegislabs

The FDA’s statement is further bolstered by newly published studies that show the TaqPath kit is not susceptible to false negative results through testing individuals infected with COVID variants because it targets three genes in testing. These novel variant strains may affect other testing methods that do not involve three gene targets. As a result, Aegis Sciences Corporation will continue to provide healthcare practitioners with sensitive and specific diagnostic test findings within a clinically meaningful turnaround time. To date, it has completed over 3 million tests.

Throughout the Pandemic, our clinical and laboratory experts team will closely monitor the scientific literature and clinical testing guidelines. Our goal is to assist physicians in making better decisions. We will continue to do so by delivering results as quickly, accurately, and technically as possible as we have in the past.